

### Oregon Health & Science University Hospital and Clinics Provider's Orders



ADULT AMBULATORY INFUSION ORDER riTUXimab-abbs (TRUXIMA) Infusion for Rheumatoid Arthritis

ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

Page 1 of 3

Patient Identification

| ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( > ) TO BE ACTIVE. |     |         |  |  |  |
|---|-----|---------|--|--|--|
| Weight:   | kg  | Height: | cm   |  |  |
| Diagnosis Code:   |     |         |  |  |  |
| Treatment Start Dat   | te: | Pa      | atient to follow up with provider on date: |  |  |

\*\*This plan will expire after 365 days at which time a new order will need to be placed\*\*

#### **GUIDELINES FOR ORDERING**

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. Hepatitis B (Hep B surface antigen and core antibody total) screening must be completed prior to initiation of treatment and the patient should not be infected. Please send results with order.
- 3. If patient is at high risk for TB exposure, a Tuberculin test must have been placed and read as negative prior to initiation of treatment (PPD or QuantiFERON Gold blood test). If result is indeterminate, a follow up chest X-ray must be performed to rule out TB. Please send results with order.
- 4. Patient should have regular monitoring for hepatitis B, infection, and renal dysfunction.

### PRE-SCREENING: (Results must be available prior to initiation of therapy):

- ☐ Hepatitis B surface antigen and core antibody total test results scanned with orders.
- ☐ Tuberculin skin test or QuantiFERON Gold blood test results scanned with orders.
- ☐ Chest X-Ray result scanned with orders if TB test result is indeterminate.

### LABS:

| ADJ. |  |
|------|--|
|      | CBC with differential, Routine, ONCE, every (visit)(days)(weeks)(months) - Circle One    |
|      | Liver Set (AST, ALT, BILI TOTAL, BILI DIRECT, ALK PHOS, ALB, PROT TOTAL), Routine, ONCE, |
|      | every (visit)(days)(weeks)(months) - Circle One  |
|      | Labs already drawn. Date:  |

### **NURSING ORDERS:**

- TREATMENT PARAMETER Hold treatment and contact provider if Hepatitis B surface antigen or core antibody total test result is positive, TB test result is positive, or if screening has not been performed.
- 2. **First infusion or prior infusion reactions**: infuse rituximab via pump (no additional filter is required) slowly at 50 mg/hr for the first hour. If no infusion related reactions are seen, increase rate gradually by 50 mg/hr every 30 minutes to a maximum of 400 mg/hr.
- 3. **Subsequent infusions if no infusion reactions**: infuse rituximab via pump at 100 mg/hr for the first hour. If no infusion related reactions are seen, increase rate gradually by 100 mg/hour every 30 minutes to a maximum of 400 mg/hour as tolerated.
- 4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes



### **Oregon Health & Science University Hospital and Clinics Provider's Orders**

ADULT AMBULATORY INFUSION ORDER riTUXimab-abbs (TRUXIMA)

# for Rheumatoid Arthritis

ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

Page 2 of 3

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.

### **PRE-MEDICATIONS:** (Administer 30 minutes prior to infusion)

- 1. acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- 2. diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, ONCE, every visit. Give either loratadine or diphenhydrAMINE, not both.
- 3. loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED if diphenhydrAMINE is not given, every visit. Give either loratadine or diphenhydrAMINE, not both.
- 4. methylPREDNISolone sodium succinate (SOLU-MEDROL), 125 mg, intravenous, ONCE, every visit

#### **MEDICATIONS:**

ı

(If insurance requires a different biosimilar agent, pharmacy will update the order per OHSU CDTM)

riTUXimab-abbs (TRUXIMA) 1000 mg in sodium chloride 0.9%, intravenous, ONCE, Infuse per nursing order

| nterval: <i>(must check one)</i> |       |  |  |  |  |  |  |
|----------------------------------|-------|--|--|--|--|--|--|
| □ Once                           |       |  |  |  |  |  |  |
| ☐ Every 2 weeks x 2 doses        |       |  |  |  |  |  |  |
| ☐ Every weeks x d                | doses |  |  |  |  |  |  |

#### HYPERSENSITIVITY MEDICATIONS:

- 1. NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (Policy HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) 20 mg, intravenous, AS NEEDED x1 dose, for hypersensitivity or infusion reaction
- 6. acetaminophen (TYLENOL) tablet, 650 mg, oral, EVERY 4 HOURS AS NEEDED for infusion related
- 7. meperidine (DEMEROL) injection, 25-50 mg, intravenous, EVERY 2 HOURS AS NEEDED for infusionrelated severe rigors in the absence of hypotension, not to exceed 50 mg/hr
- 8. sodium chloride 0.9% solution, 1000 mL, intravenous, AS NEEDED, Infuse at 200 mL/hr when infusion is stopped for emergency or PRN medications



## Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
ritliximah-abbs (TRIIXIMA)

# riTUXimab-abbs (TRUXIMA) for Rheumatoid Arthritis

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Page 3 of 3

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ✓ ) TO BE ACTIVE.

| ALL ONDERS WIGHT BE WAY   | RED IN INK WITH A CHECKINIARK ( * ) TO BE AC  | IIVE.                                 |  |
|---|---|---------------------------------------|--|
| By signing below, I represent the followin I am responsible for the care of the patient (v I hold an active, unrestricted license to practithat corresponds with state where you provid state if not Oregon); | who is identified at the top of this form);<br>ce medicine in: □ Oregon □   | (check box<br>tly licensed. Specify   |  |
| My physician license Number is #  | (MUST BE COMPLETED To scope of practice and authorized by law to  | O BE A VALID<br>order Infusion of the |  |
| medication described above for the patient ic   | entified on this form.  |                                       |  |
| Provider signature:   | Date/Time:  |                                       |  |
| Printed Name:   | Phone: Fax  | :                                     |  |
| OLC Central Intake Nurse: Phone: 971-262-9645 (providers only) Fax: 5 Please check the appropriate box for the p  |   |                                       |  |
| □ Beaverton OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006 Phone number: 971-262-9000 Fax number: 503-346-8058   | □ NW Portland Legacy Good Samaritan camp Medical Office Building 3, Suit 1130 NW 22nd Ave. Portland, OR 97210 Phone number: 971-262-9600 Fax number: 503-346-8058 | te 150                                |  |
| ☐ Gresham Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030 Phone number: 971-262-9500 Fax number: 503-346-8058  | □ Tualatin Legacy Meridian Park campus Medical Office Building 2, Suit 19260 SW 65th Ave. Tualatin, OR 97062 Phone number: 971-262-970 Fax number: 503-346-8058   | te 140                                |  |

Infusion orders located at: www.ohsuknight.com/infusionorders